Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
Jonathan Bridges, Donald CutlipBeth Israel Deaconess Medical Center, Boston, Massachusetts, USAAbstract: Coronary artery disease remains one of the leading causes of death in the United States. Over the last 30 years, the development of coronary artery angioplasty and stenting has drastically reduce...
Guardado en:
Autores principales: | Jonathan Bridges, Donald Cutlip |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9551f77810bb4ed58f3f765e14708571 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Updates on the use of ureteral stents: focus on the Resonance® stent
por: Thomas MT Turk, et al.
Publicado: (2010) -
Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery – focus on the paclitaxel eluting stent
por: Litsky J, et al.
Publicado: (2014) -
Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers
por: Brendan Doyle, et al.
Publicado: (2009) -
Everolimus-eluting coronary stents
por: Alejandro Saez, et al.
Publicado: (2010) -
Long-term effectiveness and safety of sirolimus drug-eluting stents
por: Bikkina M, et al.
Publicado: (2011)